VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

EEC 2022 | Electrographic marker to monitor treatment response in Lennox-Gastaut syndrome

Linda Dalic, MBBS, PhD Candidate, Austin Health, University of Melbourne, Heidelberg, VIC, Australia, discusses new data implicating generalized paroxysmal fast activity (GPFA) as a biomarker for changes in seizure frequency in Lennox-Gastaut syndrome (LGS). GPFA is a core electrographic feature seen in patients with LGS and can be measured using EEG. Using longitudinal EEG data from the recent randomized, controlled trial of deep brain stimulation for LGS (ESTEL; ACTRN12621001233819), GPFA burden was calculated for each patient at the end of each three-month phase of the study. When assessing the association between GPFA burden on the 24-hour EEG and diary-recorded seizure frequency, a positive correlation was seen. The percentage reduction in GPFA correlated with the percentage reduction in diary-recorded seizures. In this way, GPFA burden can be used to track treatment response in patients with LGS. This interview took place at the 14th European Epilepsy Congress (EEC) 2022 in Geneva, Switzerland.


Linda Dalic reports the following disclosures:
Consultation fees from LivaNova